# Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype

Study · id `cardio:ct-nct06486363` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06486363](<https://clinicaltrials.gov/study/NCT06486363>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06486363

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 196 participants.

## Technical summary

Registry record NCT06486363. Randomized; no masking; primary purpose treatment. Start 2024-08-01 (anticipated); primary completion 2026-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT06486363, source copy `cardio:ctgov-nct06486363-2024-07-29`, retrieved 2026-11-18)
- Planned start: 2024-08-01 (anticipated) (ClinicalTrials.gov record NCT06486363, source copy `cardio:ctgov-nct06486363-2024-07-29`, retrieved 2026-11-18)
- Primary completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT06486363, source copy `cardio:ctgov-nct06486363-2024-07-29`, retrieved 2026-11-18)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT06486363, source copy `cardio:ctgov-nct06486363-2024-07-29`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06486363-2024-07-29`, retrieved 2026-11-18)

## The registry's words

- Brief title: Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype
- Condition: Intracranial Aneurysms
- Condition: Antiplatelet Drugs
- Intervention (Drug): Aspirin combined with clopidogrel
- Intervention (Drug): Aspirin combined with half-dose ticagrelor
- Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Brain aneurysm (intracranial aneurysm) (`cardio:intracranial-aneurysm`)
- Registry lists this organization as the lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (`cardio:org-the-affiliated-nanjing-drum-tower-hospital-of-nanjing-3a906f`)

## Provenance

Content hash: d6400222290bf8499e612fe143f89cd1ed5aa1fa6419624e2f747a88f365ae1d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
